Articles related to GUIDELINES/RECOMMENDATIONS

The American Heart Association has updated infective endocarditis guidance to incorporate the 2023 Duke/ISCVID diagnostic criteria, advanced microbiologic diagnostics, contemporary imaging recommendations, and evolving antimicrobial treatment approaches while emphasizing multidisciplinary management.

The 2026 ESC heart failure guidelines redefine ejection-fraction phenotypes, formalize stages A through D, and broaden foundational therapy recommendations, including SGLT2 inhibitors and mineralocorticoid receptor antagonists across defined clinical settings.

Early detection remains one of the strongest tools against prostate cancer, with localized disease associated with nearly 100% 5-year survival. An oncology nursing review highlights screening, risk stratification, precision medicine, and the expanding role of nurses in education, care coordination, and survivorship support.

Analysis of NHANES data suggests that adoption of the 2026 ACC/AHA dyslipidemia guidelines could make approximately 25 million additional US adults eligible to consider statin therapy, primarily through incorporation of PREVENT risk equations and expanded emphasis on long-term cardiovascular risk.

Updated AAN and AHS guidance outlines when to initiate preventive migraine therapy, how to select treatments based on efficacy and tolerability, and how to tailor management for special populations and comorbidities.

Updated joint ESPGHAN/NASPGHAN guidelines for pediatric Helicobacter pylori infection emphasize antimicrobial stewardship, susceptibility-guided therapy, and more selective testing strategies. The recommendations also introduce several changes regarding screening, incidental findings, and management of associated conditions.